Font Size: a A A
Keyword [erlotinib]
Result: 41 - 60 | Page: 3 of 8
41. Efficacy And Clinical/Molecular Predictors Of Erlotinib Monotherapy For Chinese Advanced Non-small Cell Lung Cancer
42. The Effect Of Glutaminase Inhibitor-968on Cell Cycle And It’s Combining Use With Erlotinib
43. Chronopharmacology And Mechanism Of Antitumor Effect Of Erlotinib In Lewis Tumor-Bearing Mice
44. Combination Regiment Of FuZhengKangAi Decotion And Erlotinib For Advanced NSCLC Patients
45. Effect Of ABCG2on Resistance To Erlotinib In Non-small Cell Lung Cancer
46. Reversal Of Drug Resistance By β-elemene In Erlotinib-resistant Human Non-small Cell Lung Cancer A549 Cells(A549/ER): A Preliminary Experimental Study
47. Caveolin-1 Decreases The Sensibility To TKIs In Non-small Cell Lung Cancer Harboring EGFR Mutations
48. The Mechanism Of C-MET Signal Pathway,Which Is Involved In HGF Induced Non-small Cell Lung Cancer Cells To Erlotinib Resistance
49. Erlotinib Enhanced The CIK Cell-mediated Lysis To Lung Adenocarcinoma HCC827 Cells
50. Metformin Reverses The Resistance Of Erlotinib-resistant Human Lung Adenocarcinoma Cell Line A549ER In Vitro
51. Establishment Of PC9/ERlotinib Resistance Cell Line And Detect The Resistance Reversal Mechanism Of Octreotide On PC9/ERlotinib
52. Design And Synthesis Of Erlotinib Based Targeting Fluorescent Probe And Its Application In The Detection Of Lung Cancer
53. Efficacy Of Erlotinib Versus Chemotherapy In The Second-line Therapy Of Advanced Non-small-cell Lung Cancer:A Meta-Analysis
54. Small Molecular TKIs Versus Chemotherapy In EGFR Mutation-Negative, Previously Treated Non-Small-Cell Lung Cancer-meta-analysis
55. Prognostic Significance Of MicroRNA Expression In Completely Resected Lung Adenocarcinoma And The Associated Response To Erlotinib
56. The Effections Of Novel Targeting Agent Erlotinib On Human Ovarian Cancer Cell Line SKOV3
57. Synthesis And Synthetic Optimization For Erlotinib Hydrochloride
58. Research Progress Of Erlotinib Therapy For Advanced Non-Small-Cell Lung Cancer
59. Synthetic Of Factor Xa Inhibitor Betrixaban And The Key Intermediate Of EGFR Inhibitor Erlotinib
60. A Novel Histone Deacetylase Inhibitor Synergistically Enhances The Antitumor Activity Of Erlotinib In EGFR-TKI-Resistant NSCLC Cells
  <<First  <Prev  Next>  Last>>  Jump to